Orphan Medical is a development stage company the identifies and develops treatments for uncommon diseases. The company focuses on approval of three products: antizol for ethylene glucol poisoning in suicide attempts and for animals inadvertant consumption of anti-freeze; Busulfex, an IV agent for the preparative ablation of bone marrow prior to transplant; and, Xyrem, an agent to treat the severe form of narcolepsy, cataplexy. Orphan achieved record revenues of $17 M in 2002 with significant revenue growth prospects into the future primarily based on Xyrem.
|
